20.500.12556/DiRROS-12685
Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer : final analysis of the GioTag study
Aim: Final overall survival (OS) and time on treatment analysis of patients with EGFR mutation-positive non-small-cell lung cancer (NSCLC) who received sequential afatinib and osimertinib. Patients & methods: Patients (n = 203) had T790M-positive disease following first-line afatinib and started osimertinib treatment >/=10 months before data entry. Primary outcome was time on treatment; OS analysis was exploratory. Results: Median time on treatment with afatinib and osimertinib was 27.7 months (90% CI: 26.7-29.9). Median OS was 37.6 months (90% CI: 35.5-41.3); median OS was 41.6 and 44.8 months in Del19-positive patients and Asian patients, respectively. Conclusion: In real-world clinical practice, sequential afatinib and osimertinib was associated with encouraging outcomes in patients with EGFR mutation-positive NSCLC, especially in Del19-positive patients and Asian patients.
non-small cell lung carcinoma -- therapy
drug therapy
afatinib
osimertinib
GioTag study
nedrobnocelični karcinom pljuč -- terapija
terapija z zdravili
afatinib
osimertinib
raziskava GioTag
true
false
true
Future Medicine Ltd
Angleški jezik
Ni določen
© 2020 Maximilian J. Hochmair and other authors
Neznano
2020-11-18 13:29:03
2020-11-18 13:29:04
2022-08-18 03:38:49
0000-00-00 00:00:00
2020
0
Velika Britanija
0
Nasl. z nasl. zaslona;
Opis vira z dne 14. 11. 2020;
Soavtorica iz Slovenije: Tanja Cufer;
str. [1-10]
no.
Vol. 16
2020
0000-00-00
Zaloznikova
VTisku
NiDoloceno
0000-00-00
0000-00-00
0000-00-00
616-006
1744-8301
10.2217/fon-2020-0740
37424899
521824025
RAZ_Hochmair_Maximilian_J_i2020.pdf
RAZ_Hochmair_Maximilian_J_i2020.pdf
1
E5B817D1334C093553F6EC429C0A7178
a333a0786aedf6b7f40d2e5c6079b8fca560ff63fd584d1a640e4a9feaca69af
87ed06a3-17b6-11ed-b6b8-001a4af901a5
https://dirros.openscience.si/Dokument.php?lang=slv&id=17206
RAZ_Hochmair_Maximilian_J_i2020.pdf
RAZ_Hochmair_Maximilian_J_i2020.pdf
1
C384BC86E3FD51111A4BAD50BC370759
2472d6292157dd65ed53ab637f6dc02f3082c3c2c4e977f6ebf36acdb13ba153
88000995-17b6-11ed-b6b8-001a4af901a5
https://dirros.openscience.si/Dokument.php?lang=slv&id=17207
https://www.futuremedicine.com/doi/pdf/10.2217/fon-2020-0740
1
https://dirros.openscience.si/Dokument.php?lang=slv&id=15443
Univerzitetna klinika za pljučne bolezni in alergijo Golnik
0
0
0